E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic obstructive pulmonary disease |
|
E.1.1.1 | Medical condition in easily understood language |
COPD- smoking related lung disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
E.1.2 | System Organ Class | 100000015472 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the effects of the Tiotropium and olodaterol combination (Spiolto respimat 2.5/2.5ug) 2 puffs once daily vs Relvar Ellipta (fluticasone furoate 92 micrograms, vilaterol 22 micrograms) 1 puff once daily on airway bacterial load (the numbers of bacteria found) from induced sputum
|
|
E.2.2 | Secondary objectives of the trial |
To determine the effects of the Tiotropium and olodaterol combination (Spiolto respimat 2.52.5ug) 2 puffs once daily vs Relvar Ellipta (fluticasone furoate 92 micrograms, vilaterol 22 micrograms) 1 puff once daily on the airway microbiota (a technology that is very sensitive to detect bacteria). Microbiota will be characterised in sputum, oropharyngeal swabs and nasopharyngeal swabs
To determine the effects of the Tiotropium and olodaterol combination (Spiolto respimat 2.52.5ug) 2 puffs once daily vs Relvar Ellipta (fluticasone furoate 92 micrograms, vilaterol 22 micrograms) 1 puff once daily on lung inflammation caused by neutrophils using several different sputum tests
To evaluate the safety and tolerability of Tiotropium and olodaterol combination (Spiolto respimat 2.52.5ug) 2 puffs once daily vs Relvar Ellipta (fluticasone furoate 92 micrograms, vilaterol 22 micrograms) 1 puff once daily in patients previously treated with inhaled corticosteroids
To evaluate patient reported out |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male and female patients aged > 40 years • Current or ex smokers having at least a 10 pack year smoking history • A clinical diagnosis of COPD made by a physician • Post-bronchodilator FEV1/FVC ratio at screening of <70% • Moderate to Very Severe COPD (GOLD II-IV) according to consensus guidelines consisting of a post-bronchodilator FEV1 <80% predicted at screening. • Currently treated with inhaled corticosteroids (with or without long acting bronchodilators) for at least 12 months prior to screening. • Able to perform all study procedures including spirometry and questionnaires with minimal assistance • Blood eosinophil count less than 300 eosinophil cells per microlitre on bloods taken at screening. • Able to produce a sputum sample at the baseline visit (nebulised sputum induction is acceptable)
|
|
E.4 | Principal exclusion criteria |
• Inability to give informed consent • Asthma • Acute Antibiotics within 28 days prior to screening • Current use of the following: roflumilast, ritonavir, itraconazole, telithromycin, or ketoconazole (or other strong CYP3A4 inhibitors). • Systemic Immunosuppressive medication including current oral corticosteroids at a dose >5mg for >28 days. • Glomerular filtration rate (eGFR) below 30ml/min/1.73m2 or requiring dialysis. This will be determined at screening. • Use of any investigational drugs within five times of the elimination half-life after the last study dose or within 30 days, whichever is longer. • Known allergy, intolerance or contraindication to any of the study drugs • Unstable co-morbidities (cardiovascular disease, active malignancy) which in the opinion of the investigator would make the patient unsuitable to be enrolled in the study • An exacerbation of COPD occurring during the 28 days prior to screening requiring treatment with either oral corticosteroids and antibiotics. • An exacerbation requiring treatment with antibiotics or corticosteroids between the screening and randomization visit • Pregnancy or breast feeding • Women of child bearing potential (WOCBP) who are not practicing an acceptable method of contraception (see below) • Long term oxygen therapy • Lapp lactase deficiency, glucose-galactose malabsorption or another inherited disorder of galactose metabolism. Acceptable forms of contraception: • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal • progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable • intrauterine device (IUD) • intrauterine hormone-releasing system ( IUS) • bilateral tubal occlusion • vasectomised partner • sexual abstinence
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Bacterial load of total respiratory pathogens determined by quantitative polymerase chain reaction. Continuous variable at 0, 1, 2, 3 and 6 months |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Continuous variable at 0, 1, 2, 3 and 6 months |
|
E.5.2 | Secondary end point(s) |
1) Bacterial community composition determined by 16S microbiome sequencing as measured by the Shannon Diversity index. Additional outcome will be relative abundance of Haemophilus OTUs at genus level or relative abundance of proteobacteria at phylum level. Proportion of patients with dysbiosis as defined by >40% relative OTU’s of a single organism.
2) Sputum neutrophil elastase activity determined using an activity based immunoassay
3) Sputum neutrophil extracellular traps determined using a validated ELISA
4) Sputum cytokines (CXCL-8, IL17, IL-1beta, resistin, IL13)
5) Ex-vivo phagocytosis of Haemophilus tested by incubating sputum cells with FITC-labelled H. influenzae*
6) Frequency of adverse events and serious adverse events between groups
7) Quality of life using St. George’s Respiratory Questionnaire(SGRQ, COPD assessment test (CAT), MRC dyspnoea score and transitional dyspnoea index
8) Comparison of time to first exacerbation of COPD, Number of exacerbations Changes in FEV1 measurement
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Continuous variables will be evaluated using regression analysis incorporating data from all available time points (0 to 6 months) while events at fixed time points e.g tiem to first exacerbation or frequency of exacerbations over 6 months will be evaluated at the end of the follow-up period (6 months) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 29 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 29 |